|
1
|
de Groot PG and Derksen RH:
Antiphospholipid antibodies: update on detection pathophysiology,
and treatment. Curr Opin Hematol. 11:165–169. 2004.PubMed/NCBI
|
|
2
|
Miyakis S, Lockshin MD, Atsumi T, et al:
International consensus statement on an update of the
classification criteria for definite antiphospholipid syndrome
(APS). J Thromb Haemost. 4:295–306. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bas de Laat H, Derksen RH and de Groot PG:
beta2-glycoprotein I, the playmaker of the antiphospholipid
syndrome. Clin Immunol. 112:161–168. 2004.PubMed/NCBI
|
|
4
|
Mulla MJ, Brosens JJ, Chamley LW, et al:
Antiphospholipid antibodies induce a pro-inflammatory response in
first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod
Immunol. 62:96–111. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mehdi AA, Uthman I and Khamashta M:
Antiphospholipid syndrome: pathogenesis and a window of treatment
opportunities in the future. Eur J Clin Invest. 40:451–464. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xie H, Zhou H, Wang H, Chen D, Xia L, Wang
T and Yan J: Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression
in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling
pathways. Mol Immunol. 53:246–254. 2013.
|
|
7
|
Lu YC, Yeh WC and Ohashi PS: LPS/TLR4
signal transduction pathway. Cytokine. 42:145–151. 2008. View Article : Google Scholar
|
|
8
|
Zhou H, Yan Y, Xu G, et al: Toll-like
receptor (TLR)-4 mediates anti-β(2) GPI/β(2) GPI-induced tissue
factor expression in THP-1 cells. Clin Exp Immunol. 163:189–198.
2011.
|
|
9
|
Xia L, Zhou H, Hu L, et al: Both NF-κB and
c-Jun/AP-1 involved in
anti-β2GPI/β2GPI-induced tissue factor
expression in monocytes. Thromb Haemost. 109:643–651. 2013.
|
|
10
|
Lawrence MC, Jivan A, Shao C, et al: The
roles of MAPKs in disease. Cell Res. 18:436–442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou H, Chen D, Xie H, Xia L, Wang T, Yuan
W and Yan J: Activation of MAPKs in the
anti-β2GPI/β2GPI-induced tissue factor
expression through TLR4/IRAKs pathway in THP-1 cells. Thromb Res.
130:e229–e235. 2012.
|
|
12
|
Lee SH, Nam HJ, Kang HJ, Kwon HW and Lim
YC: Epigallocatechin-3-gallate attenuates head and neck cancer stem
cell traits through suppression of Notch pathway. Eur J Cancer.
49:3210–3218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sarkar FH, Li Y, Wang Z and Kong D: The
role of nutraceuticals in the regulation of Wnt and Hedgehog
signaling in cancer. Cancer Metastasis Rev. 29:383–394. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin HY, Hou SC, Chen SC, et al:
(−)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis
through inhibiting constitutive and IL-6-induced JAK/STAT3
signaling in head and neck squamous cell carcinoma cells. J Agric
Food Chem. 60:2480–2489. 2012.
|
|
15
|
Kim SJ, Jeong HJ, Lee KM, et al:
Epigallocatechin-3-gallate suppresses NF-kappaB activation and
phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG
cells. J Nutr Biochem. 18:587–596. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou H, Wolberg AS and Roubey RA:
Characterization of monocyte tissue factor activity induced by IgG
antiphospholipid antibodies and inhibition by dilazep. Blood.
104:2353–2358. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou H, Wang H, Li N, Yu Y, Huang H, Yan Y
and Wang T: Annexin A2 mediates
anti-β2GPI/β2GPI-induced tissue factor
expression on monocytes. Int J Mol Med. 24:557–562. 2009.
|
|
18
|
Xu G, Wen H, Zhou H, et al: Involvement of
IRAKs and TRAFs in anti-β2GPI/β2GPI-induced
tissue factor expression in THP-1 cells. Thromb Haemost.
106:1158–1169. 2011.PubMed/NCBI
|
|
19
|
Pierangeli SS, Vega-Ostertag ME, Raschi E,
et al: Toll-like receptor and antiphospholipid mediated thrombosis:
in vivo studies. Ann Rheum Dis. 66:1327–1333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vallabhapurapu S and Karin M: Regulation
and function of NF-kappaB transcription factors in the immune
system. Annu Rev Immunol. 27:693–733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McIntyre JA, Wagenknecht DR and Faulk WP:
Antiphospholipid antibodies: discovery, definitions, detection and
disease. Prog Lipid Res. 42:176–237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boles J and Mackman N: Role of tissue
factor in thrombosis in antiphospholipid antibody syndrome. Lupus.
19:370–378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Swadzba J, Iwaniec T and Musial J:
Increased level of tumor necrosis factor-α in patients with
antiphospholipid syndrome: marker not only of inflammation but also
of the prothrombotic state. Rheumatol Int. 31:307–313. 2011.
|
|
24
|
Agaba AE, Charaklias N, Babu-Victor A, et
al: Antiphospholipid syndrome: a series of surgical emergencies and
the current evidence for its managemen. Ann R Coll Surg Engl.
88:370–374. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Petri M: Use of hydroxychloroquine to
prevent thrombosis in systemic lupus erythematosus and in
antiphospholipid antibody-positive patients. Curr Rheumatol Rep.
13:77–80. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Les I, Guillermo RL, Munther A, et al:
Intensity and duration of anticoagulation therapy in
antiphospholipid syndrome. Semin Thromb Hemost. 38:339–347. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pierangeli SS, Colden-Stanfield M, Liu X,
Barker JH, Anderson GL and Harris EN: Antiphospholipid antibodies
from antiphospholipid syndrome patients activate endothelial cells
in vitro and in vivo. Circulation. 99:1997–2002. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gharavi AE, Pierangeli SS,
Colden-Stanfield M, Liu XW, Espinola RG and Harris EN: GDKV-induced
antiphospholipid antibodies enhance thrombosis and activate
endothelial cells in vivo and in vitro. J Immunol. 163:2922–2927.
1999.PubMed/NCBI
|
|
29
|
Pierangeli SS, Liu SW, Anderson G, Barker
JH and Harris EN: Thrombogenic properties of murine
anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and
human immunoglobulin G antiphospholipid antibodies. Circulation.
94:1746–1751. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Iglesias Jiménez E, Camacho-Lovillo M,
Falcón-Neyra D, Lirola-Cruz J and Neth O: Infant with probable
catastrophic antiphospholipid syndrome successfully managed with
rituximab. Pediatrics. 125:e1523–e1528. 2010.PubMed/NCBI
|
|
31
|
Corbacioglu S, Cesaro S, Faraci M, et al:
Defibrotide for prophylaxis of hepatic veno-occlusive disease in
paediatric haemopoietic stem-cell transplantation: an open-label,
phase 3, randomised controlled trial. Lancet. 379:1301–1309. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Espinosa G, Berman H and Cervera R:
Management of refractory cases of catastrophic antiphospholipid
syndrome. Autoimmun Rev. 10:664–668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Forastiero RR, Martinuzzo ME and de
Larrañaga GF: Circulating levels of tissue factor and
proinflammatory cytokines in patients with primary antiphospholipid
syndrome or leprosy related antiphospholipid antibodies. Lupus.
14:129–136. 2005. View Article : Google Scholar
|
|
34
|
Yoon KH: Sufficient evidence to consider
hydroxychloroquine as an adjunct therapy in antiphospholipid
antibody (Hughes’) syndome. J Rheumatol. 29:1574–1575.
2002.PubMed/NCBI
|
|
35
|
Montiel-Manzano G, Romay-Penabad Z,
Papalardo de Martínez E, Meillon-García LA, García-Latorre E,
Reyes-Maldonado E and Pierangeli SS: In vivo effects of an
inhibitor of nuclear factor-kappa B on thrombogenic properties of
antiphospholipid antibodies. Ann NY Acad Sci. 1108:540–553. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Holy EW, Stämpfli SF, Akhmedov A, et al:
Laminin receptor activation inhibits endothelial tissue factor
expression. J Mol Cell Cardiol. 48:1138–1145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Suganuma M, Sueoka E, Sueoka N, et al:
Mechanisms of cancer prevention by tea polyphenols based on
inhibition of TNF-α expression. Biofactors. 13:67–72.
2000.PubMed/NCBI
|
|
38
|
Shin HY, Kim SH, Jeong HJ, et al:
Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6
and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1
cells. Int Arch Allergy Immunol. 142:335–344. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wheeler DS, Catravas JD, Odoms K,
Denenberg A, Malhotra V and Wong HR: Epigallocatechin-3-gallate, a
green tea-derived polyphenol, inhibits IL-1 beta-dependent
proinflammatory signal transduction in cultured respiratory
epithelial cells. J Nutr. 134:1039–1044. 2004.
|
|
40
|
Lin YL and Lin JK:
(−)-Epigallocatechin-3-gallate blocks the induction of nitric oxide
synthase by down-regulating lipopolysaccharide-induced activity of
transcription factor nuclear factor-kappaB. Mol Pharmacol.
52:465–472. 1997.
|
|
41
|
Ahn SC, Kim GY, Kim JH, et al:
Epigallocatechin-3-gallate, constituent of green tea, suppresses
the LPS-induced phenotypic and functional maturation of murine
dendritic cells through inhibition of mitogen-activated protein
kinases and NF-kappaB. Biochem Biophys Res Commun. 313:148–155.
2004. View Article : Google Scholar
|
|
42
|
Youn HS, Lee JY, Saitoh SI, Miyake K, Kang
KW, Choi YJ and Hwang DH: Suppression of MyD88- and TRIF-dependent
signaling pathways of Toll-like receptor by
(−)-epigallocatechin-3-gallate, a polyphenol component of green
tea. Biochem Pharmacol. 72:850–859. 2006.
|
|
43
|
Zhang YK, Huang ZJ, Liu S, Liu YP, Song AA
and Song XJ: WNT signaling underlies the pathogenesis of
neuropathic pain in rodents. J Clin Invest. 123:2268–2286. 2013.
View Article : Google Scholar : PubMed/NCBI
|
